| Name | Hvivo |
|---|---|
| Epic | HVO |
| Isin | GB00B9275X97 |
| Index | MID300 |
| Industry | Medical Equipment and Services |
| Latest share price | 20.10p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £136.75 | Debt ratio | n/a |
| Shares in issue | 680.37 | Debt-to-equity ratio | n/a |
| P/E ratio | 18.7 | Assets / equity ratio | n/a |
| Total dividends per share | 0.20p | Price to book value | n/a |
| Dividend yield | 0.8 | ROCE | 23.61 |
| Dividend cover | 6.35 | EPS growth | 32 |
| Earning per share | 2.38 | 52-week high / low | 18.00p / 30.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-04-18 | 2024-05-20 | 0.20p |
| Special | 2023-05-04 | 2023-06-09 | 0.45p |
| Company name | Hvivo |
|---|---|
| Address | Queen Mary Innovation Centre, 42 New Road, London, United Kingdom, E1 2AX |
| Telephone | |
| Website | http://hvivo.com/ |
| Director | Position |
|---|---|
| Mr Yamin Mo' Khan | CEO |
| Dr Elaine Sullivan | Non-Executive Director |
| Mr Brendan Buckley | Non-Executive Director |
| Mr Cathal Friel | Executive Chairman |
| Mr Martin Gouldstone | Independent Non-Executive Director |
| Mr Stephen Pinkerton | CFO & Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 5.67 | 6.02 | 6.22 |
| Investments and other non-current assets | n/a | n/a | 7 |
| Total non-current assets | 31.22 | 9.15 | 16.94 |
| Inventory / work in progress | 0.43 | 0.5 | 0.66 |
| Trade and other receivables | 14.6 | 13.29 | 8.94 |
| Cash and equivalents | 36.97 | 28.44 | 15.69 |
| Other current assets and asset held for resale | n/a | n/a | 0.04 |
| Total of all assets | 83.23 | 51.38 | 42.27 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 35.18 | 29.76 | 20.69 |
| Long term liabilities | 13.72 | 1.4 | 0.9 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 48.9 | 31.16 | 21.59 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 34.33 | 20.22 | 20.68 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.68 | 0.67 | 0.67 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 38.68 | 25.04 | 25.21 |
| Share premium account | 0.52 | n/a | n/a |
| Total equity | 34.33 | 20.22 | 20.68 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 10.1 | 6.02 | 0.59 |
| Pre-tax profit | 11.15 | -0.36 | 0.28 |